AbbVie’s alliance with Gilgamesh Pharmaceuticals is pursuing next-generation psychiatric medications. The companies aim to bring patients drugs that offer the benefit of psychedelics but with a better side effect profile.
The post AbbVie Expands Psychiatric Drug Prospects, Inking R&D Pact With Neuroscience Startup appeared first on MedCity News.
Related Articles
Value-Based Care Is a Four Layer Cake — Why Do We Only Focus on The Icing?
During a recent panel discussion, three healthcare experts discussed reasons why value-based...
Value-Based Care Is a Four Layer Cake — Why Do We Only Focus on The Icing?
During a recent panel discussion, three healthcare experts discussed reasons why value-based...
State Reported Efforts to Address Health Disparities: A 50 State Review
This analysis focuses on current state efforts, many of which were implemented...
State Reported Efforts to Address Health Disparities: A 50 State Review
This analysis focuses on current state efforts, many of which were implemented...
Leave a comment